Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Nov;29(9):617-25.
doi: 10.3109/07357907.2011.621912.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer

Nan Soon Wong  1 , Kellen L Meadows, Lee S Rosen, Alex A Adjei, Scott H Kaufmann, Michael A Morse, William P Petros, Yali Zhu, Paul Statkevich, David L Cutler, Michael L Meyers, Herbert I Hurwitz
Affiliations
Clinical Trial

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer

Nan Soon Wong et al. Cancer Invest. 2011 Nov.

Abstract

We conducted a phase I study to assess safety, pharmacokinetics, pharmacodynamics, and activity of lonafarnib plus gemcitabine. Subjects received oral lonafarnib twice daily and gemcitabine on days 1, 8, and 15 every 28 days; multiple dose levels were explored. Lonafarnib had no apparent effect on gemcitabine PK. Mean lonafarnib half-life ranged from 4 to 7 hr; median T(max) values ranged from 4 to 8 hr. Two patients had partial response; seven patients had stable disease at least 6 months. Oral lonafarnib at 150 mg a.m./100 mg p.m. plus gemcitabine at 1,000 mg/m(2) is the maximum tolerated dose with acceptable safety and tolerability.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prelamin A accumulation after treatment with Lonafarnib. A.) Buccal cells were reacted with anti-rabbit prelamin A and mouse anti-lamin followed by fluorochrome-labeled secondary antibodies.
See this image and copyright information in PMC

References

    1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430. - PubMed
    1. Lobell RB. Prenylation of Ras GTPase superfamily proteins and their function in immunobiology. Adv. Immunol. 1998;68:145–189. - PubMed
    1. Schafer WR, Trueblood CE, Yang CC, Mayer MP, Rosenberg S, Poulter CD, Kim SH, Rine J. Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science. 1990;249:1133–1139. - PubMed
    1. Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 2005;7:297–300. - PubMed
    1. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U. S. A. 1989;86:8323–8327. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources